Can Lab-Grown stem cells supercharge blood recovery after transplant?

NCT ID NCT00461955

Completed Disease control Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This trial tests whether stem cells grown in the lab before being returned to the body can help blood counts recover faster after a stem cell transplant for multiple myeloma. Adults aged 18 to 65 with myeloma in first response will receive their own amplified stem cells. The main goal is to see if white blood cells and platelets recover quickly without needing transfusions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: autologous peripheral blood stem cell transplantation, ex vivo amplified
What this could lead to: If successful, this approach could speed up blood cell recovery after stem cell transplant, reducing infection risk and transfusion needs for myeloma patients.
What could go wrong: This is a small pilot study, so results may not apply broadly. There are risks of toxicity from the amplified cells and potential long-term blood or genetic abnormalities.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

CHU Haut-Leveque

Pessac, 33604, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.